MX380171B - Procesos e intermedios para preparar un medicamento. - Google Patents

Procesos e intermedios para preparar un medicamento.

Info

Publication number
MX380171B
MX380171B MX2015012731A MX2015012731A MX380171B MX 380171 B MX380171 B MX 380171B MX 2015012731 A MX2015012731 A MX 2015012731A MX 2015012731 A MX2015012731 A MX 2015012731A MX 380171 B MX380171 B MX 380171B
Authority
MX
Mexico
Prior art keywords
sup
processes
medicine
preparing
intermediate steps
Prior art date
Application number
MX2015012731A
Other languages
English (en)
Other versions
MX2015012731A (es
Inventor
Haim Cyril Ben
Matteo Conza
Ioannis Nicolaos Houpis
Philip Pye
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2015012731A publication Critical patent/MX2015012731A/es
Publication of MX380171B publication Critical patent/MX380171B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Se divulga un proceso para preparar los siguientes compuestos:(ver Fórmula) en donde R1, R1a y R2a son como se han definido en la memoria descriptiva, así como también un proceso para preparar otros intermedios que pueden ser útiles para sintetizar productos posteriores, especialmente compuestos que son útiles como medicamentos, por ejemplo, inhibidores de la tirosina-cinasa de Bruton (Btk) tal como ibrutinib; también se divulgan otros procesos, otros intermedios y compuestos perse.
MX2015012731A 2013-03-15 2014-03-11 Procesos e intermedios para preparar un medicamento. MX380171B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361786842P 2013-03-15 2013-03-15
EP13159470 2013-03-15
EP13197813 2013-12-17
PCT/EP2014/054621 WO2014139970A1 (en) 2013-03-15 2014-03-11 Processes and intermediates for preparing a medicament

Publications (2)

Publication Number Publication Date
MX2015012731A MX2015012731A (es) 2016-02-18
MX380171B true MX380171B (es) 2025-03-12

Family

ID=51535892

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015012731A MX380171B (es) 2013-03-15 2014-03-11 Procesos e intermedios para preparar un medicamento.
MX2020012596A MX2020012596A (es) 2013-03-15 2015-09-14 Procesos e intermedios para preparar un medicamento.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020012596A MX2020012596A (es) 2013-03-15 2015-09-14 Procesos e intermedios para preparar un medicamento.

Country Status (19)

Country Link
EP (1) EP2970291B1 (es)
JP (1) JP6777398B2 (es)
KR (2) KR102377688B1 (es)
CN (2) CN105026400A (es)
AU (2) AU2014230935A1 (es)
BR (1) BR112015021856A2 (es)
CA (1) CA2901510C (es)
DK (1) DK2970291T3 (es)
EA (1) EA201591685A1 (es)
ES (1) ES2924193T3 (es)
HR (1) HRP20220628T1 (es)
HU (1) HUE058914T2 (es)
LT (1) LT2970291T (es)
MX (2) MX380171B (es)
MY (1) MY194905A (es)
PE (1) PE20151652A1 (es)
SG (2) SG10201809696UA (es)
SI (1) SI2970291T1 (es)
WO (1) WO2014139970A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR122019020716B1 (pt) 2011-09-02 2021-02-17 Incyte Holdings Corporation heterociclilaminas como inibidores de pi3k e composição farmacêutica que as compreende
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
CN105884747B (zh) * 2014-08-28 2021-01-05 首药控股(北京)有限公司 一种制备布鲁顿酪氨酸激酶(btk)激酶抑制剂的制备方法
CN104447761A (zh) * 2014-11-27 2015-03-25 广东东阳光药业有限公司 一种吡唑衍生物的制备方法
CN105481862B (zh) * 2015-01-21 2018-08-21 中国科学院合肥物质科学研究院 Flt3激酶的新型抑制剂及其用途
US10266535B2 (en) 2015-01-21 2019-04-23 Hefei Institutes Of Physical Science, Chinese Academy Of Sciences Inhibitor of FLT3 kinase and use thereof
EP3262046B1 (en) * 2015-02-27 2020-11-04 Incyte Corporation Salts of pi3k inhibitor and processes for their preparation
LV15201B (lv) 2015-08-31 2017-07-20 Latvijas Organiskās Sintēzes Institūts Ibrutiniba izejvielas iegūšanas paņēmiens
CN106608877B (zh) * 2015-10-21 2018-11-13 新发药业有限公司 一种依鲁替尼中间体4-氨基-3-（4-苯氧基）苯基-1H-吡唑并[3,4-d]嘧啶的制备方法
JO3794B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون
JO3793B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv مثبطات تيروزين كاينيز بروتون وأساليب استخدامها
WO2018103058A1 (en) * 2016-12-09 2018-06-14 Janssen Pharmaceutica Nv Inhibitors of bruton's tyrosine kinase and methods of their use
WO2018145280A1 (zh) * 2017-02-09 2018-08-16 合肥合源药业有限公司 Flt3激酶抑制剂或其盐的晶型及其制备方法
CN107383017B (zh) * 2017-07-20 2020-01-14 河南师范大学 依鲁替尼高效制备方法
CN110944999A (zh) * 2017-08-01 2020-03-31 勃林格殷格翰国际有限公司 中间体化合物和方法
CN113906011B (zh) * 2019-05-21 2025-05-13 詹森药业有限公司 用于制备btk抑制剂的方法和中间体
US12215110B2 (en) 2019-05-21 2025-02-04 Janssen Pharmaceutica Nv Processes and intermediates for preparing a Btk inhibitor
CN113200987A (zh) * 2021-04-29 2021-08-03 湖南华腾制药有限公司 一种伊布替尼的制备方法
CN115322226B (zh) * 2022-08-17 2023-08-11 厦门大学 一种共价靶向砷抑制剂及其制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU780052B2 (en) * 1999-09-17 2005-02-24 Abbott Gmbh & Co. Kg Pyrazolopyrimidines as therapeutic agents
EA018573B1 (ru) * 2006-09-22 2013-09-30 Фармасайкликс, Инк. Ингибиторы тирозинкиназы брутона
CA2668286C (en) * 2006-11-03 2014-09-16 Pharmacyclics, Inc. Bruton's tyrosine kinase activity probe and method of using
CN103319488A (zh) * 2007-03-28 2013-09-25 环状药物公司 布鲁顿氏酪氨酸激酶抑制剂
UA105362C2 (en) * 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
GEP20146098B (en) 2009-03-31 2014-05-27 Boehringer Ingelheim Int 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their usage as pde9a modulators
US7718662B1 (en) * 2009-10-12 2010-05-18 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
US8962830B2 (en) * 2010-07-09 2015-02-24 The Walter And Eliza Hall Institute Of Medical Research Protein kinase inhibitors and methods of treatment
EP2632898A4 (en) * 2010-10-29 2014-04-02 Biogen Idec Inc HETEROCYCLIC TYROSINE KINASE HEMMER
WO2012158795A1 (en) * 2011-05-17 2012-11-22 Principia Biopharma Inc. Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
WO2013010136A2 (en) * 2011-07-13 2013-01-17 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
CA2881519A1 (en) * 2012-08-10 2014-02-13 Boehringer Ingelheim International Gmbh Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors
EP2914586B1 (en) * 2012-11-02 2017-04-05 Pfizer Inc. Bruton's tyrosine kinase inhibitors
CN103848810A (zh) * 2012-11-30 2014-06-11 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂

Also Published As

Publication number Publication date
MX2020012596A (es) 2021-02-09
KR20150132172A (ko) 2015-11-25
EP2970291B1 (en) 2022-05-11
LT2970291T (lt) 2022-06-10
MX2015012731A (es) 2016-02-18
EP2970291A1 (en) 2016-01-20
DK2970291T3 (da) 2022-08-01
CA2901510A1 (en) 2014-09-18
KR20210123429A (ko) 2021-10-13
SG11201507595XA (en) 2015-10-29
SG10201809696UA (en) 2018-11-29
JP6777398B2 (ja) 2020-10-28
KR102377688B1 (ko) 2022-03-22
EA201591685A1 (ru) 2016-01-29
ES2924193T3 (es) 2022-10-05
CN105026400A (zh) 2015-11-04
HUE058914T2 (hu) 2022-09-28
AU2014230935A1 (en) 2015-09-03
AU2018204086A1 (en) 2018-06-28
WO2014139970A1 (en) 2014-09-18
KR102311329B1 (ko) 2021-10-14
AU2018204086B2 (en) 2020-03-12
CN112608298A (zh) 2021-04-06
BR112015021856A2 (pt) 2017-07-18
MY194905A (en) 2022-12-22
JP2016510779A (ja) 2016-04-11
CA2901510C (en) 2022-11-29
SI2970291T1 (sl) 2022-07-29
HRP20220628T1 (hr) 2022-06-24
PE20151652A1 (es) 2015-11-12

Similar Documents

Publication Publication Date Title
MX380171B (es) Procesos e intermedios para preparar un medicamento.
ZA202109164B (en) 4 - imidazopyridazin- 1 -yl-benzamides and 4 - imidazotriazin- 1 - yl - benzamides as btk- inhibitors
MX2021007432A (es) Compuestos y composiciones para inhibir la actividad de shp2.
SA515360007B1 (ar) مركبات عطرية غير متجانسة كمثبطات بروتونز تيروسين كيناز ( btk)
JO3453B1 (ar) مشتقات البنزاميد لتثبيط نشاط abl1 و abl2 و bcr-abl1
EA201892050A1 (ru) Способ получения замещенных 5-фтор-1h-пиразолопиридинов
TN2016000268A1 (en) N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2.
EA201690246A1 (ru) Ингибиторы аутотаксинов, содержащие ядро гетероароматическое кольцо-бензил-амидный цикл
MD20150048A2 (ro) Derivaţi ai pirolotriazinonei în calitate de inhibitori ai PI3K
MX336214B (es) Derivados de pirrolotriazinona como inhibidores de pi3k.
IN2015KN00262A (es)
ECSP14026138A (es) Uracilos sustituidos bicíclicamente y uso de los mismos
PH12016500003A1 (en) Compounds and compositions as inhibitors of mek
NZ719169A (en) Heteroaryl butanoic acid derivatives as lta4h inhibitors
EA201590183A1 (ru) Производные азаиндола, выступающие в качестве ингибиторов pi3k
PH12016500985A1 (en) Use of benzimidazole-proline derivatives
CR20150160A (es) Derivados de macrólidos, su preparación y su uso terapéutico
PH12015502000A1 (en) Processes and intermediates for preparing a medicament
TH172968A (th) กระบวนการและสารมัธยันตร์สำหรับเตรียมยา
TN2013000128A1 (en) Process for preparing pan-cdk inhibitors of the formula (1), and intermediates in the preparation
UA110478C2 (ru) 3-моноетаноламіносукциноїламідо-n-(3',4'-диметилфеніл)антранілова кислота, що проявляє протизапальну, анальгетичну, діуретичну та протигрибкову активність
CR20120445A (es) Ariltriazolonas ligadas a bisarilo y su uso

Legal Events

Date Code Title Description
HH Correction or change in general